Haematology 2018

PORT Trial design

• All registered patients will receive 4 infusions of pembrolizumab given at 3 weekly intervals at a dose of 200mg. • At 12 weeks, patients will start radiotherapy : 12Gy in 3 fractions. • Patients who progress on pembrolizumab before week 12 will start radiotherapy as soon as possible after progression. • Following completion of radiotherapy patients will continue pembrolizumab until disease progression or unacceptable toxicity.

Week

0 3 6 9 12 15 18 21 24

Pembrolizumab

x x x x x x x x x

200mg i.v.

Radiotherapy 12 Gy in 3 fractions

x